Pharmaceuticals Italy

Italy Allergy Immunotherapy Market Analysis, 2024–2034

Italy Allergy Immunotherapy Market Industry Trends and Forecast to 2034: Segmented by (Type, Allergen, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Italy · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $49.4 Mn Estimated value
Estimate 2025 $53.2 Mn 2.3% of the global market
Projected 2034 $104.6 Mn 96.6% Adds $51.4 Mn over 9 forecast years
CAGR 2025–2034 7.8% Faster than 53% of 180 Pharmaceuticals markets here
Key players 5 Companies profiled
  • Italy is 2.28% of the global market.
  • In Europe, the largest is Germany at $74.3 Mn.
  • Fastest growing: Russia at 8.1% a year.
  • Italy ranks 4th of 6 by size in Europe.

Market size projection

Italy

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$51.4 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Allergy Immunotherapy Market market size by year, Italy
YearMarket sizeChange that yearSince 2025
2024 (estimate) $49.4 Mn — —
2025 (base) $53.2 Mn +$3.9 Mn —
2026 (forecast) $57.4 Mn +$4.2 Mn +7.8%
2027 (forecast) $61.9 Mn +$4.5 Mn +16.2%
2028 (forecast) $66.7 Mn +$4.8 Mn +25.3%
2029 (forecast) $71.9 Mn +$5.2 Mn +35%
2030 (forecast) $77.5 Mn +$5.6 Mn +45.6%
2031 (forecast) $83.5 Mn +$6.0 Mn +56.9%
2032 (forecast) $90.0 Mn +$6.5 Mn +69.2%
2033 (forecast) $97.1 Mn +$7.0 Mn +82.4%
2034 (forecast) $104.6 Mn +$7.6 Mn +96.6%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $2.33 Bn
  2. US $1.04 Bn
  3. North America $1.01 Bn
  4. Europe $495.0 Mn
  5. APAC $465.4 Mn
  6. China $199.5 Mn
  7. Canada $162.4 Mn
  8. Japan $136.4 Mn
  9. Latin America $113.9 Mn
  10. Middle East $83.3 Mn
  11. Germany $74.3 Mn
  12. France $67.2 Mn
  13. UK $59.9 Mn
  14. Italy (this report) $53.2 Mn
  15. Spain $50.5 Mn
  16. Brazil $51.4 Mn
  17. Ecuador $50.0 Mn
  18. Saudi Arabia $47.2 Mn
  19. India $41.0 Mn
  20. Africa $33.5 Mn
  21. Mexico $31.0 Mn
  22. Australia $28.9 Mn
  23. Russia $21.4 Mn
  24. New Zealand $21.1 Mn
  25. South Africa $14.5 Mn
  26. UAE $10.9 Mn
  27. Egypt $6.4 Mn
  28. Philippines $5.3 Mn
  29. Malaysia $3.7 Mn
  30. Hong Kong $3.6 Mn
  31. Thailand $3.2 Mn
  32. Singapore $2.6 Mn
  33. Kenya $1.8 Mn

The Italy Allergy Immunotherapy Market Analysis Executive Summary

Allergy immunotherapy gradually trains the immune system to tolerate allergens, using shots, tablets or drops.

Key segments of the allergy Immunotherapy market include type (Subcutaneous Immunotherapy, Sublingual Tablets and Sublingual Drops) and allergen (Pollen, Dust Mites and Food).

Italy Allergy Immunotherapy Market Dynamics

Market Growth Drivers

More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the allergy Immunotherapy market. Biosimilars are widening access.

Opportunity

New targets, oral drugs that replace injections and cell therapies for autoimmune disease give the allergy Immunotherapy market room to grow.

Market Restraints

High prices, infection risks with immune-suppressing drugs, patent expiries and the need for long-term treatment hold back the allergy Immunotherapy market.

Competitive Landscape for Allergy Immunotherapy Market in Italy

The allergy Immunotherapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Allergy Immunotherapy Market in Italy

Allergy Immunotherapy in Italy: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AIFA, the Italian Medicines Agency, which also negotiates prices and reimbursement.⁠[1] The National Health Service (SSN), run by the regions, gives universal cover, and AIFA decides which medicines it pays for.⁠[2] ClinicalTrials.gov lists 1 study on Allergy Immunotherapy that is recruiting, active or about to start in Italy.⁠[3]

[1] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[2] Italian Ministry of Health. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for allergy Immunotherapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Italy.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Allergy Immunotherapy right now, from free public sources.

Latest research 132 papers since 2021 (worldwide)

  1. Editorial: Allergens and allergic sensitization in Asia and the tropics-volume II. Frontiers in allergy, 2026
  2. Immunization with Virus-Like Particles Displaying Ara h 2‑Derived Peptides to Mitigate Peanut Allergy. ACS nano medicine, 2026
  3. Mannan-based oral nanovaccine rebalances intestinal immunity against food allergy. Science bulletin, 2026
  4. The Food Allergy-Eosinophilic Esophagitis Continuum: Implications for Food Allergy Immunotherapy. The journal of allergy and clinical immunology. In practice, 2026
  5. Early Allergen Introduction in Delaware: A Model to Address Healthcare Disparities and Population Healthcare Costs. Cureus, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Allergy Immunotherapy in context

Italy compared

  • Health spending per person: 3,398 US$ per person (2024). World: 1,317 US$ per person (2023). 4th highest of the 6 countries we cover in Europe.[1]
  • Doctors: 4.19 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 4th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 25.1% of people (2025). World: 10.4% of people (2025). Highest of the 6 countries we cover in Europe.[3]

Questions, answered with public data

How many clinical trials on Allergy Immunotherapy are running in Italy?
1 study is recruiting, active or about to start in Italy.[4]
How much research is published on Allergy Immunotherapy?
PubMed lists 132 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Allergy Immunotherapy in Italy? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Patient Support Programmes: Helping Patients Stay on TreatmentWHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient… Biologic Safety Testing: The Quiet Backbone of Drug MakingEvery vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches… Cell-Based Immunotherapy: Promise and PriceThe first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Italy

See all
Same topic, other categories

Related on allergies and biologics and biosimilars

See the topic